U.S. Drug Developer Capricor Places Duchenne Drug Trial on Hold U.S. Drug Developer Capricor Places Duchenne Drug Trial on Hold
Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
More News: Clinical Trials | Health | Muscular Dystrophy | Primary Care | Reflex Sympathetic Dystrophy